Clinical trial · Observational
Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma
Pilot Study on the Determination of Therapy Resistant Areas Within the Tumor in Patients With High-grade Glioma by Repeated 18F-FDG-PET-CT Scans
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Patient compliance was low.
Summary
Brief summary (as posted)
The objectives of the trial are: * To determine the localisation within the primary tumor of the therapy resistant cells, before and during radiotherapy to determine a possible accurate boost volume. * To determine changes during treatment intra- and extratumoral within the irradiated area.(Intratumoral: change of up-take - decrease, increase, change of localization/ Extratumoral: effects of temporal changes in up-take - e.g. due to oedema).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cerebral Astrocytoma, High Grade | Cerebral Astrocytoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| imaging (dynamic PET-CT scan) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients with a primary glioblastoma
- interventionNames
- Other: imaging (dynamic PET-CT scan)
Primary outcomes (1)
- measure
- To determine the localisation within the primary tumour of the therapy resistant cells, before and during radiotherapy to determine the accurate boost volume. To determine changes during treatment intra- and extratumoral within the irradiated area.
- timeFrame
- after acquisition of all planned PET CTs
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed gliomas III - IV (glioblastoma, anaplastic astrocytoma, gliosarcoma) at primary diagnosis; * WhO PFS \<= 2 * Tumours which do enhance on pre-operative imaging. * Post-operative enough visible residual tumour on PET or status after biopsy only * Age \>18 years * Availability of deep fresh frozen tissue for molecular biologic evaluation - if possible * Patient able to tolerate full course of conventional RT and follow serial scanning * No previous radiotherapy to the head and neck and brain area. * Prior neurosurgery within 6 weeks of treatment * No previous chemotherapy before treatment of the glioma. Standard radiochemotherapy with temozolomide is not excluded * No prior or concurrent medical condition which would make treatment difficult to complete. Medication with steroids is allowed. * No incapacitated patients. Exclusion Criteria: * Not histologically confirmed gliomas III - IV (glioblastoma, anaplastic astrocytoma, gliosarcoma) at primary diagnosis; * WhO PFS \> 2 * No tumours which do enhance on pre-operative imaging. * Post-operative not enough visible residual tumor on PET or status after biopsy only * Age \<18 years * No availability of deep fresh frozen tissue for molecular biologic evaluation * Patient not able to tolerate full course of conventional RT and follow serial scanning * Previous radiotherapy to the head and neck and brain area. * Prior neurosurgery not within 6 weeks of treatment * Previous chemotherapy before treatment of the glioma. * Prior or concurrent medical condition which would make treatment difficult to complete. * Incapacitated patients.
References
Publications (0)
Data not yet available